NAYZILAM
LOE ApproachingNDANASALSPRAY
Approved
May 2019
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
4/8 — Partial
NAYZILAM by UCB Pharma is understood, but it is thought to involve potentiation of gabaergic neurotransmission resulting from binding at the benzodiazepine site of the gaba a receptor. First approved in 2019.
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAYZILAM is a nasal spray formulation of midazolam, a benzodiazepine approved in May 2019 for acute seizure management. The drug works by enhancing inhibitory neurotransmission in the central nervous system to rapidly terminate seizure activity. It offers a non-invasive alternative to injectable benzodiazepines for emergency seizure treatment.
$0.028BPart D
LOE Approaching1.2 years to LOEProduct is approaching loss of exclusivity in January 2028 with moderate commercial activity (~$28M annual Part D spending), indicating a contracting brand team and transition to defensive positioning.
Mechanism of Action
understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on NAYZILAM at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.